Figure 1.
Flowchart describing the number of patients that were excluded because they were re-transplanted for another cause than CLAD resulting in 143 re-LTx. From these 143, 94 were suffering from BOS and 49 from rCLAD. After re-LTx, 40 patients re-developed CLAD of which 25 developed BOS and 13 rCLAD.